Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia a nested case-control analysis

Diabetes Care

Volumn 31, Issue 11, 2008, Pages 2086-2091

  Bodmer, Michael ^a   Meier, Christian ^a   Krähenbühl, Stephan ^a   Jick, Susan S ^b,c   Meier, Christoph R ^a,b,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; ANTIDIABETIC AGENT; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIBORNURIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COMORBIDITY; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; HYPOGLYCEMIA; INCIDENCE; LACTIC ACIDOSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; UNITED KINGDOM; CHEMICALLY INDUCED DISORDER; FACTUAL DATABASE; MIDDLE AGED; RISK; RISK ASSESSMENT; STATISTICS;

ACIDOSIS, LACTIC; AGED; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; GREAT BRITAIN; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; METFORMIN; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT; SULFONYLUREA COMPOUNDS;

EID: 59249083934     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-1171     Document Type: Article

References (23)

1. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
2. Tahrani AA, Varughese GI, Scarpello JH, Hanna FW: Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ 335: 508-512, 2007
3. Brown JB, Pedula K, Barzilay J, Herson MK, Latare P: Lactic acidosis rates in type 2 diabetes. Diabetes Care 21:1659-1663, 1998
4. Stang M, Wysowski DK, Butler-Jones D: Incidence of lactic acidosis in met- formin users. Diabetes Care 22:925-927, 1999
5. Salpeter S, Greyber E, Pasternak G, Salpeter E: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev: CD002967, 2003
6. Lalau JD, Race JM: Lactic acidosis in met- formin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf 20:377-384, 1999
7. Holstein A, Egberts EH: Risk of hypogly- cemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 111:405-414, 2003
8. Lalau JD, Mourlhon C, Bergeret A, Lacroix C: Consequences of metformin in toxication. Diabetes Care 21:2036-2037, 1998
9. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL: Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147: 386-399, 2007
10. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
11. van Staa T, Abenhaim L, Monette J: Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 50:735-741, 1997
12. Garcia Rodriguez LA, Perez Gutthann S: Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 45:419-425, 1998
13. Wood L, Martinez C: The general practice research database: role in pharmacovigi- lance. Drug Saf 27:871-881, 2004
14. Jick H, Jick SS, Derby LE: Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 302:766 - 768, 1991
15. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H: Validity of the general practice research database. Pharmacotherapy 23:686-689, 2003
16. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR: Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820 -825, 2008
17. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 163: 2594-2602, 2003
18. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA: Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 338:265-266, 1998
19. Runge S, Mayerle J, Warnke C, Robinson D, Roser M, Felix SB, Friesecke S: Met- formin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation? Diabetes Obes Metab 10:91-93, 2008
20. Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M: Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J InternMed 13: 428, 2002
21. Jennings AM, Wilson RM, Ward JD: Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 12:203-208, 1989
22. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM: Hypo- glycemia in patients with type 2 diabetes mellitus. Arch Intern Med 161:1653-1659, 2001
23. Hirai FE, Moss SE, Klein BE, Klein R: Severe hypoglycemia and smoking in a long-term type 1 diabetic population: Wisconsin Epidemiologic Study of Dia- betic Retinopathy. Diabetes Care 30:1437- 1441, 2007